SCHEMBL22983756

SCHEMBL22983756

CC1(CO)CN(Cc2ccccc2)C2(COC2)C1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.38
TSHR P16473 1/20 0.38
KMT2A Q03164 1/20 0.38
AMPD2 Q01433 3/20 0.37
GAA P10253 1/20 0.37
EPHX1 P07099 1/20 0.37
ALDH1A1 P00352 4/20 0.36
POLB P06746 1/20 0.36
ELANE P08246 2/20 0.33
CTSG P08311 1/20 0.33
PRTN3 P24158 1/20 0.33
OPRM1 P35372 1/20 0.32
KCNH2 Q12809 1/20 0.32
SIGMAR1 Q99720 1/20 0.32
EPHX2 P34913 1/20 0.32
SCD O00767 1/20 0.32
SCD5 Q86SK9 1/20 0.32
KDM4E B2RXH2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22983503 0.76 MEN1 (0.41) MEN1TSHRKMT2AAMPD2GAA
SCHEMBL20722759 0.72 EPHX2 (0.47) MEN1TSHRKMT2AALDH1A1EPHX2
SCHEMBL6133227 0.69 ALDH1A1 (0.39) MEN1TSHRKMT2AGAAALDH1A1
SCHEMBL16400295 0.69 MEN1 (0.39) MEN1TSHRKMT2AAMPD2GAA
SCHEMBL10021383 0.68 GAA (0.51) MEN1TSHRKMT2AAMPD2GAA
SCHEMBL17700194 0.68 GAA (0.53) MEN1TSHRKMT2AAMPD2GAA
SCHEMBL19463747 0.66 GAA (0.57) MEN1TSHRKMT2AGAAALDH1A1
SCHEMBL5692162 0.66 GAA (0.41) MEN1TSHRKMT2AAMPD2GAA
SCHEMBL29585955 0.66 MCHR1 (0.44) MEN1KMT2AKCNH2SIGMAR1EPHX2
SCHEMBL24999609 0.66 ABCB1 (0.38) MEN1TSHRKMT2AAMPD2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122079960-A Alkynyl quinazoline compounds 2026-05-26 CN disclosed
EP-4013749-B1 ALKYNYL QUINAZOLINE COMPOUNDS BLACK DIAMOND THERAPEUTICS INC (US) 2026-03-11 EP disclosed
US-20260049063-A1 ALKYNYL QUINAZOLINE COMPOUNDS BLACK DIAMOND THERAPEUTICS INC (US) 2026-02-19 US disclosed
US-12435046-B2 Alkynyl quinazoline compounds BLACK DIAMOND THERAPEUTICS, INC. (US) 2025-10-07 US disclosed
CN-119390683-A Alkynyl quinazoline compounds 黑钻治疗公司 2025-02-07 CN disclosed
US-20220298120-A1 ALKYNYL QUINAZOLINE COMPOUNDS BLACK DIAMOND THERAPEUTICS, INC. 2022-09-22 US disclosed
EP-4013749-A1 ALKYNYL QUINAZOLINE COMPOUNDS Black Diamond Therapeutics, Inc. (US) 2022-06-22 EP disclosed
WO-2021030711-A1 ALKYNYL QUINAZOLINE COMPOUNDS BLACK DIAMOND THERAPEUTICS, INC. (US) 2021-02-18 WO disclosed
WO-2021030711-A1 ALKYNYL QUINAZOLINE COMPOUNDS BLACK DIAMOND THERAPEUTICS, INC. (US) 2021-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12435046-B2 Alkynyl quinazoline compounds GLS, GLS2, MCL1 MEN1 1389/4885TSHR 2974/4885KMT2A 4174/4885
US-20220298120-A1 ALKYNYL QUINAZOLINE COMPOUNDS GLS, GLS2, MCL1 MEN1 1389/4885TSHR 2974/4885KMT2A 4174/4885
US-20260049063-A1 ALKYNYL QUINAZOLINE COMPOUNDS H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, BCL6 MEN1 1318/4885TSHR 730/4885KMT2A 3453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.